We use cookies to help provide you with the best possible online experience. Please read our Privacy Policy for information about which cookies we use and what information we collect on our site. By continuing to use this site, you agree that we may store and access cookies on your device.
The letter requests that the provision for manufacturing and stockpiling of COVID-19 vaccine under clinical trial for marketing authorisation for sale or distribution should be implemented for non-COVID-19 vaccines as well.